Abstract：
Cancer immunotherapy is a promising strategy in cancer management, including hepatocellular carcinoma (HCC). This experimental study aimed to evaluate interleukin-10 (IL-10) as a biomarker for monitoring the response of tumor-derived autophagosomes vaccine in inducing antitumor immunity in HCC induced mice. It was conducted on 56 BALB/c mice; divided into 20 normal and 36, cancer induced with human liver cancer cell line (HepG2) cells. The latter group was subdivided into a positive control group (n=6) and a treated group (n=30), that was subdivided into 3 subgroups: (A) treated with dendritic cells (DC) vaccine only, (B) treated with vaccine named Dribbles only, and (C) treated with DC plus Dribbles. Serum IL-10 was assessed after immunotherapy. The mean percentage of tumor volume reduction in mice vaccinated by DC plus Dribbles was significantly superior to DC and Dribbles groups (p= 0.013, and p= 0.043, respectively). There was a statistically significant difference in IL-10 levels between different immunotherapy groups (p= 0.0003). As the mean IL-10 level was 19.50 pg/ml for the positive control group, 13 pg/ml for Dribbles group, 10 pg/ml for DCs group and 3.50 pg/ml for DCs plus Dribbles group. We conclude that DC-Dribbles vaccine has a remarkable efficacy superior to either Dribbles alone or DC alone in the decline of HCC development and survival improvement. IL-10 is a predictive biomarker for response after immunotherapy.
摘要：
癌症免疫疗法是癌症管理中一种有前途的策略，包括肝细胞癌（HCC）。这项实验研究旨在评估白细胞介素-10（IL-10）作为生物标志物，用于监测肿瘤衍生自噬体疫苗在HCC诱导的小鼠中诱导抗肿瘤免疫的反应。在56只BALB/c小鼠上进行；分为20只正常和36只人肝癌细胞系（HepG2）诱导的癌症。后一组分为阳性对照组（n=6）和治疗组（n=30），被细分为3个亚组：（A）仅用树突状细胞（DC）疫苗处理，(B)只接受名为Dribbles的疫苗治疗，和（C）用DC加Dribbles处理。免疫疗法后评估血清IL-10。通过DC加Dribles疫苗接种的小鼠中肿瘤体积减少的平均百分比显著优于DC和Dribbles组(分别为p=0.013和p=0.043)。不同免疫疗法组之间的IL-10水平存在统计学上的显著差异(p=0.0003)。阳性对照组的平均IL-10水平为19.50pg/ml，Dribbles组的13pg/ml，10pg/ml的DC组和3.50pg/ml的DC加Dribbles组。我们得出的结论是，DC-Dribbles疫苗在HCC发展下降和生存改善方面具有优于单独Dribbles或单独DC的显着功效。IL-10是免疫疗法后反应的预测性生物标志物。
